Information disclosure in Dexma Dexgate
CVE-2023-42666
The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requests for obtaining the information of the version about the web server used.
Vulnerability class: Information Disclosure
Published · last modified .
CVSS v3 metric
CVSS v3 base score 5.3 (Medium). Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N.
EPSS exploit prediction
EPSS: 0.005 (38.9th percentile), scored .
Very low probability of exploitation in the next 30 days; routine patching cadence is appropriate. 39th percentile — 38.9% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.
EPSS over last 30 days · oldest: 0.004 · newest: 0.005 · change: +0.001
Affected products
- Dexma Dexgate — versions 20130114, version 20130114
Weakness classification (CWE)
References
- www.cisa.gov/news-events/ics-advisories/icsa-23-271-02 (US Government Resource, Third Party Advisory)
Frequently asked questions
- What is CVE-2023-42666?
- CVE-2023-42666 is a medium-severity vulnerability in Dexma Dexgate, classified under Information Disclosure. CVSS score: 5.3/10. Published 2023-10-19.
- How severe is CVE-2023-42666?
- Medium severity. CVSS v3 base score is 5.3 out of 10.